 Fluoxetine
"Fluoxetine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
| Descriptor ID |
D005473
|
| MeSH Number(s) |
D02.092.831.280
|
| Concept/Terms |
Fluoxetine- Fluoxetine
- Fluoxetin
- N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
|
Below are MeSH descriptors whose meaning is more general than "Fluoxetine".
Below are MeSH descriptors whose meaning is more specific than "Fluoxetine".
This graph shows the total number of publications written about "Fluoxetine" by people in this website by year, and whether "Fluoxetine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 1 | 0 | 1 | | 1990 | 1 | 0 | 1 | | 1991 | 2 | 0 | 2 | | 1994 | 1 | 1 | 2 | | 1995 | 1 | 0 | 1 | | 1997 | 0 | 4 | 4 | | 1998 | 3 | 1 | 4 | | 1999 | 3 | 0 | 3 | | 2000 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2005 | 3 | 0 | 3 | | 2006 | 2 | 0 | 2 | | 2007 | 0 | 2 | 2 | | 2008 | 1 | 0 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2012 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Fluoxetine" by people in Profiles.
-
Swanson LM, Burgess HJ, Huntley ED, Bertram H, Mooney A, Zollars J, Dopp R, Hoffmann R, Armitage R, Todd Arnedt J. Relationships between circadian measures, depression, and response to antidepressant treatment: A preliminary investigation. Psychiatry Res. 2017 06; 252:262-269.
-
Hollander E, Soorya L, Chaplin W, Anagnostou E, Taylor BP, Ferretti CJ, Wasserman S, Swanson E, Settipani C. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. Am J Psychiatry. 2012 Mar; 169(3):292-9.
-
Isingrini E, Belzung C, d'Audiffret A, Camus V. Early and late-onset effect of chronic stress on vascular function in mice: a possible model of the impact of depression on vascular disease in aging. Am J Geriatr Psychiatry. 2011 Apr; 19(4):335-46.
-
Prasad B, Radulovacki M, Olopade C, Herdegen JJ, Logan T, Carley DW. Prospective trial of efficacy and safety of ondansetron and fluoxetine in patients with obstructive sleep apnea syndrome. Sleep. 2010 Jul; 33(7):982-9.
-
Rothschild AJ, Dunlop BW, Dunner DL, Friedman ES, Gelenberg A, Holland P, Kocsis JH, Kornstein SG, Shelton R, Trivedi MH, Zajecka JM, Goldstein C, Thase ME, Pedersen R, Keller MB. Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. Psychopharmacol Bull. 2009; 42(3):5-20.
-
Olatunji BO, Feldman G, Smits JA, Christian KM, Zalta AK, Pollack MH, Simon NM. Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: impact of anxiety sensitivity on response to pharmacotherapy. Depress Anxiety. 2008; 25(2):167-71.
-
Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Dunlop BW, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen R, Yan B, Ahmed S, Schmidt M, Ninan PT. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry. 2007 Dec 15; 62(12):1371-9.
-
Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry. 2007 Aug; 68(8):1246-56.
-
Anagnostou E, Esposito K, Soorya L, Chaplin W, Wasserman S, Hollander E. Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder. J Clin Psychopharmacol. 2006 Aug; 26(4):444-6.
-
Simon NM, Zalta AK, Worthington JJ, Hoge EA, Christian KM, Stevens JC, Pollack MH. Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder. Depress Anxiety. 2006; 23(6):373-6.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|